This trial will test whether GSK3511294 is effective and safe in people with severe uncontrolled asthma that is characterized by high levels of eosinophils.
1 Primary · 5 Secondary · Reporting Duration: Baseline (Day 1) and Week 52
2 Treatment Groups
Participants receiving GSK3511294 (Depemokimab)
1 of 2
Participants receiving placebo
1 of 2
375 Total Participants · 2 Treatment Groups
Primary Treatment: GSK3511294 (Depemokimab) · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age Any Age · All Participants · 11 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|GSK Investigational Site||100.0%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
Frequently Asked Questions
How many test subjects are a part of this experiment?
"Yes, the information on clinicaltrials.gov suggests that this trial is actively searching for participants. The trial was initially posted on 3/17/2021 and was most recently updated on 10/18/2022. The study is enrolling 375 patients between 33 locations." - Anonymous Online Contributor
What is the margin of safety for GSK3511294 (Depemokimab)?
"GSK3511294 (Depemokimab) has been rated as a 3 in terms of safety. This is due to being a Phase 3 trial, which provides some evidence of efficacy as well as multiple rounds of data supporting its safety." - Anonymous Online Contributor
Are we still enrolling individuals for this clinical research project?
"The website clinicaltrials.gov has the most recent information on this trial, which is actively recruiting patients. The study was created on 3/17/2021 and was last edited on 10/18/2022." - Anonymous Online Contributor
How many locations are conducting this research?
"This study is enrolling at 33 sites, which are situated in and around San Antonio, Houston, and Cypress. Please choose the location most convenient for you to limit travel-related impact on your life if you decide to participate." - Anonymous Online Contributor